Have a feature idea you'd love to see implemented?
Let us know!
EW Edwards Lifesciences Corp
Price (delayed)
$74.81
Market cap
$44.12B
P/E Ratio
10.78
Dividend/share
N/A
EPS
$6.94
Enterprise value
$41.15B
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of
Highlights
The company's EPS has surged by 195% YoY and by 186% QoQ
The net income has soared by 191% YoY and by 182% from the previous quarter
The debt has grown by 2.3% YoY
Key stats
What are the main financial stats of EW
Market
Valuations
Earnings
Shares outstanding
589.8M
Market cap
$44.12B
Enterprise value
$41.15B
Price to earnings (P/E)
10.78
Price to book (P/B)
4.72
Price to sales (P/S)
7.61
EV/EBIT
9.47
EV/EBITDA
9.09
EV/Sales
7.01
Revenue
$5.87B
Gross profit
$4.58B
Net income
$4.16B
EBIT
$4.35B
EBITDA
$4.53B
Free cash flow
$515.5M
Per share
Balance sheet
Liquidity
EPS
$6.94
EPS diluted
$6.93
Free cash flow per share
$0.86
Book value per share
$15.86
Revenue per share
$9.83
TBVPS
$17.43
Total assets
$12.97B
Total liabilities
$3.36B
Debt
$706.7M
Equity
$9.55B
Working capital
$4.78B
Debt to equity
0.07
Current ratio
3.46
Quick ratio
2.7
Net debt/EBITDA
-0.66
Margins
Efficiency
Dividend
EBITDA margin
77.1%
Gross margin
78%
Net margin
70.8%
Operating margin
25.7%
Return on assets
39.4%
Return on equity
54.1%
Return on invested capital
71.2%
Return on capital employed
39.4%
Return on sales
74%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EW stock price
How has the Edwards Lifesciences stock price performed over time
Intraday
1.19%
1 week
2.03%
1 month
7.58%
1 year
0.93%
YTD
-1.89%
QTD
13.37%
Financial performance
How have Edwards Lifesciences's revenue and profit performed over time
Revenue
$5.87B
Gross profit
$4.58B
Operating income
$1.51B
Net income
$4.16B
Gross margin
78%
Net margin
70.8%
The net income has soared by 191% YoY and by 182% from the previous quarter
The net margin has soared by 177% from the previous quarter and by 164% YoY
EW's revenue is up by 10% year-on-year
EW's gross profit is up by 8% year-on-year and by 2.2% since the previous quarter
Growth
What is Edwards Lifesciences's growth rate over time
Valuation
What is Edwards Lifesciences stock price valuation
P/E
10.78
P/B
4.72
P/S
7.61
EV/EBIT
9.47
EV/EBITDA
9.09
EV/Sales
7.01
The company's EPS has surged by 195% YoY and by 186% QoQ
The price to earnings (P/E) is 75% lower than the 5-year quarterly average of 43.0 and 65% lower than the last 4 quarters average of 30.4
The stock's price to book (P/B) is 52% less than its 5-year quarterly average of 9.8 and 30% less than its last 4 quarters average of 6.7
The equity has grown by 43% year-on-year and by 28% since the previous quarter
The P/S is 28% below the 5-year quarterly average of 10.6 and 12% below the last 4 quarters average of 8.6
EW's revenue is up by 10% year-on-year
Efficiency
How efficient is Edwards Lifesciences business performance
The company's return on invested capital has surged by 162% QoQ and by 147% YoY
EW's return on assets has surged by 158% since the previous quarter and by 143% year-on-year
Edwards Lifesciences's return on equity has surged by 156% QoQ and by 134% YoY
The company's return on sales has surged by 154% QoQ and by 141% YoY
Dividends
What is EW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EW.
Financial health
How did Edwards Lifesciences financials performed over time
The total assets is up by 38% year-on-year and by 28% since the previous quarter
The company's total liabilities rose by 29% QoQ and by 27% YoY
The debt is 93% less than the equity
The equity has grown by 43% year-on-year and by 28% since the previous quarter
The company's debt to equity fell by 30% YoY and by 22% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.